MedTrace Logo

A Study in Subjects With Moderate Atopic Dermatitis

NCT03175354 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2018-10-25

No results posted yet for this study

Summary

This is a randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of ALX-101 Gel 1.5% and 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 42 days to adult and adolescent subjects with moderate atopic dermatitis.

Conditions

Interventions

DRUG

ALX-101 Gel 1.5% and ALX-101 Gel Vehicle

Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle

DRUG

ALX-101 Gel 5% and ALX-101 Gel Vehicle

Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle

Sponsors & Collaborators

  • Ralexar Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-26
Primary Completion
2018-06-29
Completion
2018-06-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03175354 on ClinicalTrials.gov